Chapter 44: Antihyperlipidemics & Peripheral Circulation Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive.

It is really great to have you with us.

Today, we are opening up a massive file.

I mean, we are really getting into the weeds, or maybe I should say into the chapter 44 from pharmacology,

a patient -centered nursing process approach, the 12th edition.

It is a dense chapter, no doubt about it, but it's also one of the most critical ones that we've covered.

The title is a bit of a mouthful.

Anti -Hyperlipidemics and Drugs to Improve Peripheral Blood Flow.

It sounds incredibly technical, I know, but if you sort of strip away the jargon, we're really talking about the plumbing of the human body.

Okay, the plumbing.

I like that analogy.

Yeah, we're talking about what happens when the pipes get clogged with fat, which is the anti -hyperlipidemic part, and then what happens when the blood itself becomes too thick or the vessels too narrow to get blood to your fingers and toes.

And that's the peripheral blood flow part.

That's the peripheral blood flow part, exactly.

So for our listeners, whether you're a nursing student who is just trying to survive pharmacology, or you're a lifelong learner who wants to understand what those meds in the cabinet actually do,

this one is for you.

We are going to unpack the classifications, the mechanisms like how do these things actually work inside the cell, and crucially, the nursing considerations.

Because in this text, specifically this patient -centered approach, it's not just about memorizing a drug name, it's about safety.

It's about knowing that if you mix drug A with drug B, you might cause a massive internal bleed, or that if a patient complains of a leg cramp, it might not just be a cramp, it could be their muscles actively disintegrating.

That sounds terrifying, and we are definitely going to get into that later.

But let's set the stage with some definitions before we dive into the deep end.

We have anti -hyperlipidemics.

A simple definition to start.

These are drugs used to lower blood lipids, or lipoproteins.

You might hear them called anti -lipidemics or hypo -lipidemics in other contexts, but this textbook sticks with anti -hyperlipidemics.

And their job is basically to scrub the grease out of the blood.

Is that fair?

That's a great way to put it, yeah.

Scrubbing the grease.

And then we have the drugs for blood flow.

Right.

So we have peripheral vasodilators.

Peripheral meaning away from the heart's hands, feet, legs.

And vasodilators, meaning they dilate or widen the blood vessels.

These are for vessels that have been narrowed usually by something like a vasospasm.

And then there's a category that sounds like something you'd buy at an auto parts store.

Blood viscosity reducer agents.

It does sound mechanical, doesn't it?

But it's actually about decreasing the thickness, the viscosity of the blood itself.

And believe it or not, it involves increasing the flexibility of the red blood cells.

Their flexibility.

Yeah.

So they can literally squeeze through tight spots.

I love that image.

Flexible blood cells just squishing their way through narrow pipes.

Okay.

So here's our roadmap for the hour.

Yeah.

We are going to follow the chapter structure exactly.

We'll start with the physiology.

What are these lipoproteins actually made of?

Then we'll hit the lipid -lowering drugs, starting with the non -statins, and then moving to the main event, which is the statins.

The heavy weights.

Then we'll look at non -pharmacologic methods, and finally we'll switch gears to the peripheral artery disease drugs.

It's a very logical flow.

You have to understand the fat before you can treat the fat.

So let's start at the beginning.

Section one.

The physiology of lipoproteins.

When we talk about cholesterol or triglycerides, they aren't just floating around free in the blood, are they?

No.

And that is a key concept to grasp right at the beginning.

Lipids, cholesterol, triglycerides, phospholipids, they're all fats.

Blood is mostly water.

And as we all learned in kindergarten,

oil and water don't mix.

Right.

If you just dumped raw cholesterol into the bloodstream, it would clump up and cause an embolism almost immediately.

It'd be catastrophic.

So the body needs some kind of transport system.

A vehicle.

Exactly.

To transport these lipids through the bloodstream, the body packages them.

Imagine a tiny submarine.

The outer hull is made of protein.

This protein carrier binds the lipids inside.

That entire package, the protein shell plus the fatty cargo, is what we call a lipoprotein.

Okay, so it's a vehicle for the fat.

Precisely.

And the text categorizes these vehicles into four major groups based on their density and their composition.

And density in this context basically means the ratio of protein to fat.

Exactly.

Protein is heavy and dense, fat is light and fluffy.

So more protein means higher density.

And this classification gives us the famous good versus bad cholesterol distinction, right?

That's where it comes from.

Let's break those down.

First up, the friendly one, HDL.

High density lipoprotein.

This is the good guy.

Why is it the hero of the story?

What makes it good?

Well, two reasons.

First is structural.

It's the smallest and densest of the lipoproteins because it contains more protein and less fat than the others.

Okay, so it's a lean machine.

Right.

And second, functionally, its job is essentially waste management.

HDL patrols the bloodstream, kind of like a garbage truck.

It removes cholesterol from the blood and from the tissue walls, and it delivers it back to the liver.

And the liver gets rid of it.

Yes, the liver excretes it in the bile.

So it's taking the trash out of the system.

You want a lot of these sanitation trucks on the road.

Okay, that makes sense.

So then we have the villain of the story, LDL.

Low density lipoprotein, the bad lipoprotein.

And structurally, this one contains 50 to 60 % of cholesterol.

That is a huge load of cholesterol in one single particle.

And what's the danger?

What happens if you have too much of it?

Well, if you have elevated LDL, or if those LDL particles get damaged by things like inflammation or smoking, they tend to drop their cargo, that cholesterol gets deposited right into the arterial wall.

It's just dumb in its trash on the side of the road.

It is.

And that trash builds up.

The risk is significantly greater for developing atherosclerotic plaques and ultimately heart disease.

Okay.

Then we have the LDL.

Very low density lipoprotein.

Now, the main cargo here isn't really cholesterol.

It's it carries mostly triglycerides and less cholesterol.

VLDL is basically the delivery truck for energy fat.

It takes fat from the liver to your cells for fuel.

Got it.

And finally, the last one is chylomicrons.

These are the massive cargo ships.

They're huge particles composed almost entirely of triglycerides.

Their job is to transport the fatty acids and cholesterol you just ate from your diet out of the intestine and over to the liver.

Now, the text mentions something inside that protein shell called apolipoproteins.

This sounds a bit more technical.

Do we really need to get into this?

You do, because clinical practice is really moving in this direction.

It's becoming more important.

Think of apolipoproteins as part of the structure of that protein shell.

They're like the address labels or the key fobs for the lipoprotein.

Okay.

So they tell it where to go and what to do.

Pretty much.

The text highlights a few specific ones.

There's APOA1, which is the major component of HDL, the good stuff.

And then there's APOB.

And I'm guessing APOB is on the bad stuff.

Essentially, yes.

APOB is the major component of LDL.

It actually exists in two forms, APOB100 and APOB48.

But the text makes a really interesting point here.

APOB100 includes VLDL as well as LDL.

So it's on two of the bad lipoproteins.

Right.

And because of that, measuring your APOB100 level is actually a better indicator of risk for coronary artery disease or CAD than just measuring LDL alone.

That's really interesting.

Why is it a better indicator?

Because your standard LDL cholesterol test, the LDLC, measures the weight of the cholesterol inside the particles.

But the APOB test measures the number of particles.

Why does that matter?

Well, you could have a normal total weight of cholesterol, but if it's spread out over thousands of small, dense, really dangerous particles, your risk is huge.

The APOB test catches that particle number, which is what actually causes the plaque.

So looking at the protein shell, the vehicle itself, tells you more than just looking at the cargo.

Exactly.

It's a more accurate picture of the traffic jam in your arteries.

Let's talk numbers.

The text provides table 44 .1, which analyzes serum lipid values.

These are the numbers patients see on the lab reports.

And nurses see in the charts all the time.

We need to know what's safe and what's scary.

Right.

These serve as baseline values.

If you're a nurse, you'll see these on admission or during annual physicals.

Let's start with total cholesterol.

The desirable range is 150 to 200 milligrams per deciliter.

And when do we start worrying?

Moderate risk starts right at 200.

High risk is anything greater than 240.

So if you see a 250 on a chart, that's a red flag that needs attention.

Okay.

What about triglycerides?

The desirable range here is 40 to 150.

Higher levels imply risk, and they're often linked to things like high sugar intake and

diabetes.

Makes sense.

And LDL, the bad guy.

For LDL, you want that floor to be low.

Desirable is less than 100.

If it's between 100 and 130, you're in a low risk zone, maybe just needs some lifestyle changes.

But high risk really kicks in at anything greater than 160.

And finally, HDL, our cleanup crew.

Here, higher is better.

You want more of those garbage trucks.

Desirable is greater than 60 milligrams per deciliter.

If you are below 35, that is considered high risk.

It means you don't have enough cleanup trucks on the road to handle all the waste.

Exactly.

The trash is piling up faster than you can haul it away.

Got it.

So that's the physiology.

Now, let's say a patient has hyperlipidemia,

too much fat in the blood.

We need to treat it.

The chapter introduces the anti -hyperlipidemics.

Right.

And there are several groups here that the text lays out.

We have bile acid sequestrants, fibrates, nicotinic acid, cholesterol absorption inhibitors, and of course, the statins.

Let's start with the non -statins.

These are often the older drugs or the ones used as add -ons.

The first group mentioned is the bile acid sequestrants.

These were actually one of the very first anti -hyperlipidemics ever used.

The prototype mentioned in the text is colostiramine.

How does it work?

It sounds like it's doing something to the bile.

The name gives it away.

It sequesters bile acids.

It acts like a magnet, but only in the intestine.

It binds with bile acids.

And what happens then?

Well, normally your body is really efficient.

It recycles bile.

But when this drug binds to it, you can't reabsorb it.

You just poop it out.

You've excrete it in the stool.

Okay.

So you lose bile.

How does that lower cholesterol in the blood?

It's a clever indirect mechanism.

The liver uses cholesterol as the raw material to make bile acids.

So when the drug binds up all the bile and you lose it, the liver senses a shortage.

It says, hey, we need more bile.

It has to work overtime to make more.

Exactly.

And to do that, it pulls more LDL cholesterol out of the blood to use as building blocks.

So by forcing the liver to make new bile, it indirectly reduces the amount of LDL floating around in your serum.

That is a very clever mechanism.

But I notice a very specific administration detail in the text about colostiramine.

It sounds unpleasant.

Yes.

It comes as a powder.

And the text doesn't mince words.

It describes it as a gritty powder.

Sounds appetizing.

Exactly.

And you absolutely cannot just swallow it dry.

If you try, you could choke or aspirate it into your lungs.

It must be mixed thoroughly in water or juice.

And you have to let it sit for a minute to fully dissolve.

And because it works entirely in the gut, I'm guessing the side effects are very GI focused.

100%.

Think about what it's doing.

It's this gritty powder that sits in your gut and binds things up.

So the side effects are what you'd expect.

Constipation is a big one,

flashulence, cramping.

It's not a pleasant experience for the patient.

Is there a better option in this class?

The text mentions a couple others.

Yes, thankfully.

The text highlights a newer drug called cholesterol.

It works the exact same way, binding bile acids, but it has far fewer side effects, less constipation, less cramping.

And does it interact with vitamins?

I remember reading that was an issue.

That's the other huge advantage.

The older agents like cholesterolamine could literally strip your body of fat soluble vitamins A, D, E, and K.

How does that happen?

Well, you need fat to absorb those vitamins.

If the drug is binding up the bile acids, which are essential for fat digestion, then you don't absorb the fat and you don't absorb the vitamins that travel with it.

So you take the fat out, you take the vitamins out.

You do.

But colicilum has much less effect on vitamin absorption.

So for all those reasons, colicilum is usually the first choice if you're going to use a bile acid sequestrant today.

That makes sense.

Let's move to the next group.

Fibric acid derivatives, or fibrates.

We have gemfibrozil and phenofibrate.

What is their specific lane?

So while the sequestrants were primarily for LDL, fibrates are the specialist for reducing triglyceride and VLDL levels.

If a patient comes in with sky -high triglycerides, what the text calls type V hyperlipidemia, this is often the drug of choice.

But there is a massive warning with these drugs regarding interactions.

This feels like a board exam question just waiting to happen.

It absolutely is.

And it's a critical nursing safety point that you cannot miss.

Fibrates are highly protein -bound.

Can you explain that concept again for the listeners?

What does protein -bound mean in practice?

Sure.

Imagine the proteins in your blood, like albumin, are seats on a bus.

Drugs need to sit in those seats to be transported safely through the body.

Only the drug that is not in a seat, the free drug, is active and can do its job.

Fibrates are very aggressive.

They take up a lot of seats, like 90 % or more.

Now imagine your patient is also taking warfarin, which is a common anticoagulant.

Warfarin also needs those seats on the bus.

So they're competing for the same seat.

They're competing.

And the fibrate often wins.

It's a stronger binder.

So it kicks the warfarin off the protein and out of its seat.

And warfarin that isn't in a seat?

Is free drug.

And free drug is active drug.

So suddenly, even though the patient took their normal dose of warfarin, the amount of active warfarin in their system skyrocks.

Which means their blood gets way too thin.

It means bleeding.

Potentially fatal bleeding, yes.

So the nursing implication is huge.

If a patient is on gemfibrazil and warfarin, the anticoagulant dose usually needs to be reduced.

And the INR, the lab test for clotting time, must be monitored very, very closely.

That is a do -not -miss interaction.

For

Okay, next up, nicotinic acid, or niacin, also known as vitamin B3.

Niacin is interesting because it's actually very effective.

It reduces VLDL and LDL, and it also raises HDL.

The text says its effect on the lipid profile is highly desirable.

It really cleans up the numbers across the board.

But there's a but, isn't there?

I feel a but coming.

There is a huge but.

The tolerability is poor.

I mean, really poor.

The text states that only 20 % of patients can initially tolerate niacin.

Only 20%.

That's an abysmal compliance rate.

Why?

What's the problem?

The side effects are just miserable for most people.

The big one, the one it's famous for, is the niacin flush.

What does that feel like?

Within minutes of taking it, the skin turns bright red.

The patient feels a burning heat, especially in their face and chest.

It's caused by a release of prostaglandins.

It can be incredibly scary if you aren't expecting it.

Wow.

What else?

A lot of GI disturbances, abnormal liver function tests, hyperlycemia, so it can raise blood sugar, which is bad for diabetics, and hyperuricemia, which is high uric acid.

That can trigger a painful gout attack.

Is there any way to manage that flushing?

It sounds like the main deal breaker.

There is a strategy.

With proper counseling and very careful titration, meaning you start with a tiny dose and slowly work up over weeks, you can build tolerance.

But the real trick mentioned in the text is aspirin.

Aspirin.

How does that help?

Yes.

The flushing is caused by prostaglandins.

Aspirin blocks prostaglandin production.

So the text suggests concomitant use of aspirin.

If you take an aspirin about 30 minutes before the niacin, it can dramatically reduce or even prevent the flushing.

And does that improve tolerance?

It does.

With that strategy, tolerance can be increased from that initial 20 % up to maybe 60 or 70%.

That's a significant improvement.

But because of the side effect profile, niacin is usually reserved for specific situations, right?

It's not a first line drug anymore.

Right.

It's for when triglycerides are just massively high, like over 500.

Or if the patient simply can't tolerate any other treatments.

It's rarely the first choice.

Okay.

The last non -statin group is the cholesterol absorption inhibitors.

The drug here is ezetimibe.

This one has a really unique and targeted mechanism.

It acts directly on the cells in the small intestine to inhibit the absorption cholesterol from your diet.

So it blocks the cholesterol in the cheeseburger you just ate from ever getting into your system.

Exactly.

It stands at the door of the intestinal cell and says you can't come in.

It decreases dietary cholesterol absorption, which in turn lowers serum cholesterol, LDL, and triglycerides.

Is it very powerful on its own?

Not really.

The text notes that for optimum effect, it must be combined with a statin, like simvastatin.

On its own, it causes only a small increase in HDL and a modest drop in LDL.

But when you add it to a statin, you get a great one -two punch.

How so?

The statin is shutting down the liver's production of cholesterol, and the ezetimibe is blocking cholesterol from coming in from the diet.

You're attacking the problem from two different angles.

That makes perfect sense.

And that brings us to the main event.

The heavyweights.

The statins.

Or, if we want to be fancy, HMG -CoA reductase inhibitors.

The champions of lipid control.

These drugs, I mean, they completely revolutionize cardiology.

Why are they called HMG -CoA reductase inhibitors?

It's such a mouthful.

Because that is exactly what they do.

To understand statins, you have to understand the factory.

Your liver manufactures about 75 % of your body's cholesterol.

Inside the liver, there's an enzyme called HMG -CoA reductase.

That enzyme is the foreman of the factory.

It's the rate -limiting step.

It controls the speed of the entire cholesterol biosynthesis pathway.

Instead of blocking absorption in the gut, like ezetimibe or binding bile like the sequesterins, statins go straight to the source.

Exactly.

They go right into the liver and they inhibit that enzyme.

They shut down the factory line.

So when the liver realizes it can't make its own cholesterol, it panics a little.

It needs cholesterol for other functions.

So it responds by putting up more LDL receptors on its surface, which pull more LDL out of the blood to satisfy its needs.

So it acts as a vacuum for the LDL in the blood.

Precisely.

By inhibiting synthesis, they decrease the concentration of cholesterol, they decrease LDL, and they also slightly increase HDL.

And they are fast.

The text says you can see LDL reduction as early as two weeks after starting therapy.

The test lists quite a few of them.

We have atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, pitavastatin, rosevastatin.

It's a big family.

And the text highlights that rosevastatin and atorvastatin are, you know, among the most prescribed drugs in the entire United States.

If you're a nurse, you will see these on medication lists constantly.

Being common doesn't mean they are without risk, though.

Let's talk adverse effects and safety.

What does the nurse need to watch for?

The early complaints are often pretty mild.

GI disturbances, headaches, muscle cramps, and fatigue.

But there are three major safety areas, three body parts really, that you have to watch very closely.

Okay, what's the first one?

The liver.

Statins work in the liver and they can stress it.

Serum liver enzymes must be monitored.

Your AST, your ALT.

If they start to spike, it could be a sign of liver injury and you might have to stop the drug.

Okay, liver.

What's number two?

The eyes.

This one surprises a lot of people.

The text explicitly states an annual eye exam is needed because there is a risk of tateract formation with long -term statin use.

I feel like that one gets missed a lot in general conversation.

Take in a heart pill.

Go check your eyes.

It does get missed, but it's right there in the guidelines.

It's a key patient touching point.

And the third one is the big warning,

rhabdomyolysis.

That is a scary word, rhabdomyolysis.

Everyone taking a statin needs to know about this.

Break that down for us.

What is it exactly?

It's essentially muscle disintegration.

The muscle fibers, for reasons not fully understood, start to break down.

When they break down, they release their contents into the bloodstream.

And what's in there that's so bad?

A protein called myoglobin.

Myoglobin is a very large molecule and it's toxic to the kidneys.

It gets to the kidneys and it clogs up the filtering units.

So you go from muscle pain to acute kidney failure.

Yes.

And it can be fatal.

It is a true medical emergency.

So what does a patient need to look out for?

What do we tell them?

The patient must be taught to report any unexplained muscle aches or weakness immediately.

If a patient on a statin calls you and says, my legs are aching and I feel really weak, you don't tell them to take a Tylenol and rest.

You tell them to come in to get their CPK levels checked right away.

Got it.

Now there's also a very serious warning about stopping these drugs.

Yes, the rebound effect.

The text emphasizes that anti -hyprolipidemic therapy is a lifetime commitment.

You're managing a chronic condition.

You're not curing an infection.

Okay.

If you abruptly start taking a statin, it can cause a three -fold rebound effect.

Three -fold.

What does that mean?

It means your liver, which has been depressed, goes into overdrive.

Your lipid levels can spike to three times their baseline.

This massive sudden spike can destabilize plaque, form a clot, and potentially lead to an acute myocardial infarction, a heart attack, and death.

Wow.

So you absolutely can't just quit cold turkey because you ran out of pills on Friday and the pharmacy is closed for the weekend.

No.

That is a critical life -or -death teaching point for patients.

Adherence is not optional.

Let's look at the prototype drug detailed in the text.

Atorvastatin.

Lipitor.

Okay.

Let's look at pharmacokinetics first.

Like the fibrates, atorvastatin is highly protein -downed, about 98%.

It has a pretty long half -life of 14 hours, which is why usually one dose a day works just fine.

And what about its pharmacodynamics?

How quickly does it work?

The peak concentration in the blood is about one to two hours after you take it, but the full therapeutic effect on your cholesterol levels takes about two to six weeks.

Patience is key.

You won't see the full benefit on your lab report for at least a month.

There is a specific interaction listed for atorvastatin that is famous.

We can't talk statins without talking about a certain fruit.

Grapefruit juice.

Why is that little fruit such a big problem?

It's all about biochemistry.

Atorvastatin is metabolized.

It's broken down by a specific liver enzyme called CYP3A4.

Grapefruit juice contains compounds that strongly inhibit that enzyme.

So if you block the enzyme that cleans up the drug...

The drug can't be cleaned up.

It builds up in your system.

If you drink grapefruit juice, it causes a significant increase in the drug concentration in your blood.

You are effectively overdosing yourself.

And more drug means a higher risk of toxicity, including that rhabdomyolysis we just talked about.

Absolutely.

The risk of all the side effects goes way up.

So no grapefruit juice with breakfast if you're on atorvastatin.

Or many other statins.

Correct.

It's a strict contraindication.

Not even a little bit.

Before we move to the nursing process, the chapter takes a moment to cover some other important labs and non -pharmacologic methods.

Let's talk about homocysteine.

This is a lab marker that's getting a lot more attention in recent years.

Homocysteine is an amino acid.

It's a byproduct of protein breakdown.

You get it from eating things like eggs, chicken, beef, cheddar, cheese.

And what's the normal reference value?

When you're fasting, it should be between 4 to 17 millimoles per liter.

And why do we care about it?

It's not cholesterol.

No, but high levels are strongly linked to cardiovascular disease, stroke, and even Alzheimer's.

The text explains that high serum homocysteine can damage the inner lining of blood vessels, the endothelium.

So it's like scratching the inside of the pipes.

That's a perfect analogy.

It creates little nicks and scratches.

It promotes thickening and loss of flexibility in the vessel.

It makes the vessels vulnerable to plaque buildup.

Can we fix it?

Can you lower it?

Yes.

And the treatment is actually quite simple and responsive to vitamins.

Three specific B vitamins can lower serum homocysteine levels, vitamin B6, vitamin B12, and folic acid.

Simple enough.

What about high sensitivity C reactive protein or HSCRP?

This is a test for inflammation.

Standard CRP is produced in the liver in response to any tissue injury or inflammation like if you have an infection or an injury.

But the high sensitivity version, the HSCRP, is valuable for detecting the very low grade chronic inflammatory protein associated with CAD.

Why is this useful if we're already checking cholesterol?

This is the scary part, and the text notes this.

Approximately one third of people who have had a heart attack have normal cholesterol and normal blood pressure.

One third?

That's a huge number.

I had no idea.

It is.

So if their cholesterol is normal, why did they have a heart attack?

The answer is often inflammation.

The HSCRP can help predict risk in those patients.

A positive test indicates a high risk for CAD because it detects that inflammatory process caused by unstable plaque buildup.

Okay, let's talk non -drug methods, diet and lifestyle, the foundation of everything.

Always the first line of defense.

The diet recommendation is to reduce saturated fats and dietary cholesterol.

Total fat should be less than 30 % of your caloric intake, and cholesterol intake should be less than 300 mg per day.

And choosing lean meats like chicken and fish over beef, that sort of thing.

Right, but the text gives a reality check here that I found really validating for patients who struggle with this.

What does it say?

It says that diet alone typically only lowers total cholesterol by about 10 % to 30%.

Why so little?

That seems discouraging.

It might seem that way, but it's important to understand why.

It's because 75 % to 85 % of serum cholesterol is endogenously derived.

Endogenously meaning?

Meaning your body makes it internally.

Your liver is pumping it out based on your genetics and other factors.

You could eat zero cholesterol, literally nothing but lettuce, and your liver would still be making cholesterol.

That explains why some people with really great diets still have high numbers.

Exactly.

It's not necessarily a failure of willpower, it's physiology.

But that doesn't mean lifestyle doesn't matter.

Exercise walking, biking is incredibly important, and smoking cessation is huge.

Smoking increases LDL, it decreases HDL, and it damages the arteries directly.

It's a triple negative.

The chapter also lists some complementary therapies, herbal interactions.

We tend to think herbs are safe, but...

Not here.

Not with these drugs.

Just a rapid -fire list of things to watch out for.

Black cohosh can increase liver enzymes, which is bad if you're on a statin.

Chinese skullcap and ginkgo biloba can increase the drug levels of statins, raising the toxicity risk.

What else?

Green tea can increase side effects.

And St.

John's wort, which people take for depression, actually decreases the effect of statins.

It makes them work less effectively.

So as always, natural doesn't mean interaction -free.

Never.

The nurse must always ask the patient what supplements, herbs, and vitamins they are taking.

Let's put all this together into the nursing process for anti -hyperlipidemics.

Section 5 of our roadmap, let's talk assessment.

First thing, you're checking vital signs and you're getting baseline serum chemistry, that full lipid panel, but also AST and ALT for the liver, and a CPK to check for any pre -existing muscle damage.

And history is important, too.

Yes, crucial.

You need a medical history.

Statins are contraindicated in active liver disorders and in pregnancy.

You absolutely need to know that before you give the first pill.

Okay, then planning.

The goal should be specific and measurable.

The patient's cholesterol will be less than 200 milligrams per deciliter in six to eight weeks.

Interventions and monitoring.

This is where the nurse's job really comes in.

It is.

The schedule for labs is laid out clearly.

You check a lipid profile every six to eight weeks for the first six months, and then every three to six months after that.

And you have to remind the patient to fast for that blood draw, right?

Yes, that's a key instruction.

They must fast for 12 to 14 hours for that lipid profile to be accurate.

Only water, no coffee.

What about the liver monitoring?

You'll monitor their ALT, ALP, and GGT.

The text notes that a slight transient increase might be normal when they first start the drug, but you should recheck it in about a week.

If it keeps going up, that's a problem.

And patient teaching.

We've hit a few of these, but let's recap the really big ones.

Okay, number one.

This is a lifetime commitment with a lag time for effect.

Don't expect instant results.

Two, get that annual eye exam.

Three, if you are on gemfibrozil and warfarin, watch for any signs of bleeding, bleeding gums, unusual bruising, dark tori stools.

Four, mix your powders like colostermine really well.

Five, report any unexplained muscle tenderness immediately.

That's the rhabdo warning.

And six, do not abruptly stop taking statins because of that rebound MI risk.

Comprehensive.

Okay, let's pivot.

We are moving from the blood content to the blood flow.

Section six, drugs to improve peripheral blood flow.

This section focuses on PAD or peripheral arterial disease, which is sometimes called PVD, peripheral vascular disease.

We are shifting our focus from the heart and the liver down to the legs and feet.

And what does that look like in a patient?

What are the symptoms?

Numbness or coolness of the extremities.

The skin might look pale or shiny.

And a classic symptom called intermittent claudication.

Define that for us.

Claudication is pain and weakness of a limb, usually the calf that happens when walking, but there are no symptoms at rest.

So it only hurts when you use it.

Exactly.

It's a classic supply and demand issue.

You walk, your leg muscles demand more oxygen -rich blood.

The arteries are clogged with plaque, so the blood can't get there.

The muscle screams in pain from lack of oxygen.

You stop walking, the demand drops, and the pain stops.

And the cause is the same stuff we've been talking about.

Pretty much.

Arteriosclerosis and hyperlipidemia leading to occlusion, a blockage of the arteries.

It's very common in older adults.

And the text notes that diabetes increases the risk two to four times.

The text mentions peripheral vasodilators as a treatment.

Right, these are drugs that dilate blood vessels.

But here is an important nuance the text makes.

They are generally more effective for disorders resulting from vasospasm, like Raynaud's disease, than they are for a fixed, hard occlusion.

Raynaud's disease is where cold or emotion triggers spasms of the fingers and toes, right?

They turn white and blue.

Exactly.

The vessels just clamp down tight.

Vasodilators work well there because they can force that spasming vessel to relax and open up.

For arteries that are blocked with HOD plaque, their efficacy is a bit more questionable.

But they are still used.

And what drug classes does it mention?

It mentions alpha blockers like prezosin, calcium channel blockers like niophatopine, and several antiplatelets like clopidogrel, aspirin, and celostazol.

And interestingly, it says statins can help here too.

Yes, individuals with PAD who are taking statins may see an improvement in their claudication symptoms.

It helps stabilize the plaque and reduce inflammation, which can improve flow a bit.

Let's zoom in on the specific drugs for PAD that the chapter highlights.

We have two main ones, celostazol and pentoxifiline.

Let's start with celostazol because it's the prototype.

What's its mechanism?

How does it work?

It's a dual action drug.

First, it is an antiplatelet, so it inhibits platelet aggregation, which makes the blood less sticky and helps prevent clots from forming on the plaque.

And it also acts as a direct acting vasodilator, especially in the femoral vasculature, the main arteries of the legs.

So it stops clots and it opens the pipes at the same time.

Correct.

So it's specifically indicated for intermittent claudication.

What about its pharmacokinetics?

It's highly protein bound between 95 and 98 percent.

And it has a half life of about 11 to 13 hours.

Side effects.

Since it's a vasodilator, you have to think about what happens when you open up blood vessels everywhere in the body.

Blood pools and blood pressure can drop.

So you get headache from blood rushing to the head, tachycardia, as the heart races to compensate for the drop in pressure, palpitations and orthostatic hypotension.

That's the dizziness when you stand up too fast.

Exactly.

Also, for some reason, diarrhea and abnormal stools are quite common.

And how long does it take to work?

Patients want to know.

The onset is slow.

It can take anywhere from two to 12 weeks.

Patients shouldn't expect a miracle overnight.

They have to stick with it.

Now, I want to clarify an interaction.

The text mentions grapefruit juice again with this one.

Yes.

It seems to pop up everywhere, doesn't it?

Grapefruit juice and also green tea can increase the levels of psilostazole.

So they should be avoided.

We're seeing a clear pattern here with cardiovascular drugs and grapefruit.

And there's a contraindication regarding heart failure.

Yes.

The text lists heart failure as a contraindication.

The fluid shifts and the demands on the heart caused by widespread vasodilation can really stress a failing heart and make the condition worse.

OK, let's address a slight confusion I found in the text regarding taking psilostazole with food.

I feel like this happens in textbooks sometimes, and it's good to clarify.

Ah, yes.

The good old text versus chart dilemma.

It's a classic.

Right.

In the main body of the text, under the diet section, it says, suggest, take with meals if GI disturbance occurs.

But then in the prototype drug chart, specifically in the dosage section, it says, 30 minutes before or two hours after morning and evening meals, do not administer with grapefruit juice.

Those seem to contradict each other.

This is a perfect nursing school scenario.

Here is how to interpret that.

The optimal absorption, the pharmacokinetically perfect way to take it, is on an empty stomach.

That's the 30 minutes before or two hours after rule that gives you the maximum drug in the blood.

But as we just mentioned, this drug causes a lot of diarrhea and GI upset.

If the patient is miserable,

they are not going to take the drug.

Compliance will be zero.

So the text offers a practical nursing intervention.

If the patient has severe GI side effects, taking it with meals might help them tolerate it and stay on the therapy, even if it slightly affects the overall absorption.

So follow the chart for the best results, but use the text's advice for problem solving if the patient can't stomach it.

Exactly.

But strictly speaking, if you are being tested on administration, the chart instruction is the standard protocol.

Got it.

That's a great clarification.

Now the second drug,

Pentoxifyline.

This is the viscosity reducer.

This one is fascinating.

It's classified as a blood viscosity reducer agent and also a platelet aggregation inhibitor.

And the mechanism involves the red blood cells themselves, which is so cool.

It is.

It improves microcirculation and tissue perfusion by decreasing blood viscosity.

And this is the really cool part, improving erythrocyte flexibility.

Erythrocytes are red blood cells.

Right.

In these narrowed, plaque -filled peripheral vessels, red blood cells often have to squeeze through single file.

If the cells are stiff, they get stuck and clog everything up.

Pentoxifyline makes them more flexible.

It literally makes them squishy so they can slide through those tight spots without getting stuck.

That is incredible cellular engineering.

It really is.

It increases tissue oxygenation simply because the blood can finally get where it needs to go.

It's used for intermittent claudication and also for burger disease.

What about side effects?

Overdoses can cause tachycardia, hypotension, and blurred vision.

The more common side effects at normal doses are often nausea and vomiting.

And administration.

Definitely take it with food to help handle that nausea.

Right.

And importantly,

the patient must avoid smoking.

Nicotine is a potent vasoconstrictor, which completely counteracts what you are trying to do with the drug.

It's like pressing the gas and the brake at the same time.

Section 8, nursing process for peripheral blood flow drugs.

Let's start with assessment.

You're doing a focused assessment.

You are looking for signs of inadequate blood flow power, coldness, pain, weak pulses, and you're getting baseline vitals.

BP and HR are absolutely crucial because, again, these are vasodilators.

They are designed to drop blood pressure and they will raise the heart rate in response.

Interventions.

You're going to monitor for that tachycardia, and especially for orthostatic hypotension.

You have to be proactive about fall prevention with these patients.

And patient teaching.

Timeline management is key.

The therapeutic response may take 1 .5 to 3 months.

Tell them not to give up after week one.

Lifestyle changes.

Crucial.

They have to stop smoking.

It will completely negate the drug's effect.

And they need to change position, slowly dangle their legs off the side of the bed for a minute before standing up to avoid passing out from orthostatic hypotension.

And alcohol.

Avoid it.

Alcohol is also a vasodilator.

Combined with one of these drugs, it can cause a severe hypotensive reaction, a double drop in blood pressure.

It's a dangerous combination.

We are coming down the homestretch.

Section 9, clinical judgment and a case study application.

The text presents a case study that really ties a lot of this together.

Let's walk through it.

Sounds good.

So the scenario is a patient who had a heart attack, an MI, three years ago.

He was prescribed Gemfibrasil 600 milligrams twice daily.

But his cholesterol remained high, around 220 to 240.

And his LDL was stuck at 140.

So his drug was changed to Simvastatin 20 milligrams per day.

OK.

First question.

How does Simvastatin differ from Gemfibrasil?

It's all about mechanism and target.

Simvastatin is a statin, an HMG -CoA reductase inhibitor.

It works in the liver to stop cholesterol production.

Gemfibrasil is a fibrite.

And why the switch?

Why not just increase the Gemfibrasil?

Because they were using the wrong tool for the job.

Remember our specialists.

Fibrates are the specialists for trachlycerides.

Statins are the specialists for LDL reduction.

Since the patient's total cholesterol and LDL were the stubborn numbers that weren't moving, the statin is the much better tool for that specific problem.

The provider matched the drug to the specific lab value that needed fixing.

What kind of monitoring does this patient need now that he's on the statin?

He needs his liver enzymes checked.

So AST and ALT.

And he needs a baseline CPK level checked to watch for that muscle damage we talked about.

And when do we recheck the lipid levels to see if it's working?

In about six to eight weeks.

Now here's a good clinical question.

Could he take both?

Could we just add the statin to the Gemfibrasil he was already on?

This is a bit of a trick question.

The text does mention combination therapy in one of its tables.

But generally, we are very, very cautious about this specific combination.

Why is that?

Because combining a fibrate and a statin significantly increases the risk of rhabdomyolysis.

It's like doubling the potential for muscle toxicity.

While it's sometimes done by specialists in severe cases, the case study implies a switch was made to avoid that additive risk and to target the LDL more effectively and safely.

And finally, let's just hit the key takeaways from the review questions that are provided in the chapter to really lock in this knowledge.

Sure.

Three big points to take home from this whole chapter.

First, know your ranges.

Total cholesterol should be less than 200.

That's your baseline for safety and patient goals.

Second,

understand the mechanism of azetame.

It inhibits the absorption of dietary cholesterol in the intestines.

It's the doorman for fat.

Got it.

And third, understand pentoxify line.

It decreases blood viscosity and improves erythrocyte flexibility.

It makes red blood cells squishy so they can get through clogged pipes.

And that brings us to the end of our deep dive into chapter 44.

We made it through the fat and the flow.

It was a lot, but we did it.

To summarize,

we went from the good and bad cholesterol HDL and LDL all the way to the specific drugs that manage them.

We covered the gritty powders of bile acid sequestrants, the serious bleeding risks of fibrates, the infamous flushing of niacin, and of course the blockbuster statins with their critical liver and muscle warnings.

And we didn't forget the peripheral drugs.

Opening up the vessels in the legs with celostazole and making blood cells flexible with pentoxify line.

The final thought here, and the text emphasizes this right in the title.

Patient -centered.

Absolutely, that's the whole point.

It's not just about throwing a pill at a number on a lab report.

It's about the diet.

It's about monitoring the liver and the eyes.

It's about understanding that these therapies are a lifetime commitment and teaching the patient why they are taking them and what to look out for.

And keeping them safe from things like rhabdomyolysis or from a fall caused by orthostatic hypotension.

That is the essence of nursing pharmacology.

Understanding the mechanism to anticipate the risks and ensure patient safety.

Well said.

Thank you to everyone for listening.

This has been the Last Minute Lecture team helping you digest the heavy stuff one deep dyes at a time.

Stay curious and keep learning.

We'll see you on the next one.